JP2024020417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024020417A5 JP2024020417A5 JP2023194557A JP2023194557A JP2024020417A5 JP 2024020417 A5 JP2024020417 A5 JP 2024020417A5 JP 2023194557 A JP2023194557 A JP 2023194557A JP 2023194557 A JP2023194557 A JP 2023194557A JP 2024020417 A5 JP2024020417 A5 JP 2024020417A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- particles
- lung disease
- interstitial lung
- ylmethylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 26
- 238000009472 formulation Methods 0.000 claims 20
- 239000002245 particle Substances 0.000 claims 11
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 6
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 claims 5
- 159000000000 sodium salts Chemical class 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 1
- 229940038472 dicalcium phosphate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000006069 physical mixture Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006079.4A GB202006079D0 (en) | 2020-04-24 | 2020-04-24 | New composition |
| GB2006079.4 | 2020-04-24 | ||
| JP2022540540A JP7387903B2 (ja) | 2020-04-24 | 2021-04-23 | 経口投与用の新しい乾燥粉末組成物 |
| PCT/GB2021/050994 WO2021214488A1 (en) | 2020-04-24 | 2021-04-23 | New dry powder composition for peroral administration |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540540A Division JP7387903B2 (ja) | 2020-04-24 | 2021-04-23 | 経口投与用の新しい乾燥粉末組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024020417A JP2024020417A (ja) | 2024-02-14 |
| JP2024020417A5 true JP2024020417A5 (https=) | 2024-05-01 |
Family
ID=71080269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540540A Active JP7387903B2 (ja) | 2020-04-24 | 2021-04-23 | 経口投与用の新しい乾燥粉末組成物 |
| JP2023194557A Pending JP2024020417A (ja) | 2020-04-24 | 2023-11-15 | 経口投与用の新しい乾燥粉末組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540540A Active JP7387903B2 (ja) | 2020-04-24 | 2021-04-23 | 経口投与用の新しい乾燥粉末組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11844868B2 (https=) |
| EP (2) | EP4389212A3 (https=) |
| JP (2) | JP7387903B2 (https=) |
| KR (1) | KR20230005220A (https=) |
| CN (1) | CN115697309A (https=) |
| AU (1) | AU2021260923B2 (https=) |
| BR (1) | BR112022021511A2 (https=) |
| CA (1) | CA3180646A1 (https=) |
| DK (1) | DK4138790T3 (https=) |
| ES (1) | ES2976885T3 (https=) |
| GB (1) | GB202006079D0 (https=) |
| IL (1) | IL297373B1 (https=) |
| LT (1) | LT4138790T (https=) |
| MX (1) | MX2022013070A (https=) |
| PL (1) | PL4138790T3 (https=) |
| PT (1) | PT4138790T (https=) |
| SI (1) | SI4138790T1 (https=) |
| WO (1) | WO2021214488A1 (https=) |
| ZA (1) | ZA202211460B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| WO2023152503A1 (en) | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| JP2008502699A (ja) | 2004-06-14 | 2008-01-31 | セプラコール・インコーポレイテッド | 肺疾患治療方法、及びそのための組成物 |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US20080139483A1 (en) * | 2006-12-12 | 2008-06-12 | Gorczynski Richard J | Drug combination for hypertensive disorders |
| CN103476410B (zh) * | 2011-01-11 | 2020-02-21 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| CN107405406A (zh) | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| WO2019183513A1 (en) | 2018-03-22 | 2019-09-26 | University Of Iowa Research Foundation | Compositions and methods for the treatment and prevention of muscular dystrophy |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
-
2020
- 2020-04-24 GB GBGB2006079.4A patent/GB202006079D0/en not_active Ceased
-
2021
- 2021-04-23 PL PL21724012.6T patent/PL4138790T3/pl unknown
- 2021-04-23 JP JP2022540540A patent/JP7387903B2/ja active Active
- 2021-04-23 CN CN202180042663.8A patent/CN115697309A/zh active Pending
- 2021-04-23 CA CA3180646A patent/CA3180646A1/en active Pending
- 2021-04-23 PT PT217240126T patent/PT4138790T/pt unknown
- 2021-04-23 DK DK21724012.6T patent/DK4138790T3/da active
- 2021-04-23 WO PCT/GB2021/050994 patent/WO2021214488A1/en not_active Ceased
- 2021-04-23 MX MX2022013070A patent/MX2022013070A/es unknown
- 2021-04-23 SI SI202130130T patent/SI4138790T1/sl unknown
- 2021-04-23 IL IL297373A patent/IL297373B1/en unknown
- 2021-04-23 EP EP24154507.8A patent/EP4389212A3/en active Pending
- 2021-04-23 BR BR112022021511A patent/BR112022021511A2/pt unknown
- 2021-04-23 AU AU2021260923A patent/AU2021260923B2/en active Active
- 2021-04-23 ES ES21724012T patent/ES2976885T3/es active Active
- 2021-04-23 LT LTEPPCT/GB2021/050994T patent/LT4138790T/lt unknown
- 2021-04-23 EP EP21724012.6A patent/EP4138790B1/en active Active
- 2021-04-23 KR KR1020227039916A patent/KR20230005220A/ko active Pending
-
2022
- 2022-03-17 US US17/696,984 patent/US11844868B2/en active Active
- 2022-10-19 ZA ZA2022/11460A patent/ZA202211460B/en unknown
-
2023
- 2023-10-23 US US18/491,946 patent/US12605341B2/en active Active
- 2023-11-15 JP JP2023194557A patent/JP2024020417A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024020417A5 (https=) | ||
| KR101554374B1 (ko) | 구강 붕해정 | |
| ES2311500T3 (es) | Particulas farmaceuticas de sabor enmascarado. | |
| JP5808670B2 (ja) | 弱塩基性薬物を含む組成物及び徐放性剤形 | |
| AU728526B2 (en) | Pharmaceutical formulations comprising amoxocyllin and clavulanate | |
| ES2274625T3 (es) | Comprimidos desintegrables en la boca que comprenden un bencimidazol. | |
| ES2351612T3 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer. | |
| TWI686215B (zh) | 祛鐵斯若(deferasirox)之口服配方 | |
| TWI750143B (zh) | 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| DK158540B (da) | Orale, ikke-retarderede dipyridamolformer og fremgangsmaade til deres fremstilling | |
| US20040166162A1 (en) | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid | |
| JP7336388B2 (ja) | 錠剤及びその製造方法 | |
| KR20140007364A (ko) | 구강내 붕괴정 | |
| JP2010524926A (ja) | ウルソデオキシコール酸の高用量組成物 | |
| BR112020008940A2 (pt) | preparação de liberação controlada | |
| HU228823B1 (en) | Swallowable tablets with high content of n-acetylcysteine | |
| JP2005139085A (ja) | 顆粒 | |
| JP6366794B2 (ja) | 原薬の化学的安定性や服用感を向上した、口腔内崩壊錠 | |
| ES2604307T3 (es) | Comprimido de disgregación oral revestido por vía seca | |
| ES3050159T3 (en) | High dose tranexamic acid composition and process for preparation thereof | |
| WO2019098327A1 (ja) | 速溶性薬物の苦味が抑制された口腔内崩壊錠 | |
| JPWO2019074826A5 (https=) | ||
| CN103126994B (zh) | 含决奈达隆的固体药物组合物 | |
| WO2025046633A1 (en) | Extended-release formulations for cilnidipine and their manufacturing processes | |
| JPH08259446A (ja) | 持効性医薬製剤 |